Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.77 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15926179 | 0.87 | NPSR1 (1.00) | NPSR1ALOX15KDM4ESMN1; SMN2NPC1 | |
| SCHEMBL9298408 | 0.85 | NPSR1 (0.56) | NPSR1BRD4KDM4ESMN1; SMN2NPC1 | |
| SCHEMBL9530889 | 0.85 | NPSR1 (0.70) | NPSR1BRD4ALOX15KDM4ESMN1; SMN2 | |
| SCHEMBL9297778 | 0.85 | NPSR1 (0.54) | NPSR1BRD4KDM4ESMN1; SMN2CA12 | |
| SCHEMBL1053554 | 0.84 | NPSR1 (0.53) | NPSR1BRD4ALOX15KDM4EIRAK4 | |
| SCHEMBL9298306 | 0.84 | NPSR1 (0.68) | NPSR1BRD4ALOX15KDM4ESMN1; SMN2 | |
| Bromide SCHEMBL9297499 | 0.83 | NPSR1 (0.66) | NPSR1BRD4ALOX15KDM4ESMN1; SMN2 | |
| SCHEMBL15865607 | 0.83 | NPSR1 (0.51) | NPSR1BRD4ALOX15KDM4ESMN1; SMN2 | |
| SCHEMBL9533171 | 0.82 | NPSR1 (0.64) | NPSR1BRD4ALOX15KDM4ESMN1; SMN2 | |
| SCHEMBL4664171 | 0.81 | NPSR1 (0.79) | NPSR1ALOX15SMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-25 | — | — | US | disclosed |
| EP-1326835-A1 | BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-07-16 | — | — | EP | disclosed |
| WO-2002028835-A1 | BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-04-11 | — | — | WO | disclosed |
| US-5371097-A | Antiulcer agents | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-12-06 | — | — | US | disclosed |
| US-5364871-A | Antiulcer agents | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-11-15 | — | — | US | disclosed |
| EP-0575614-A1 | THIAZOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-12-29 | — | — | EP | disclosed |
| WO-1992016526-A1 | THIAZOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-10-01 | — | — | WO | disclosed |
| CN-1050191-A | New thiazole derivative, they the preparation method and contain their pharmaceutical composition | FUJISAWA PHARMACEUTICAL CO (JP) | 1991-03-27 | — | — | CN | disclosed |
| EP-0417751-A2 | New thiazole derivatives, processes for the preparation thereof and pharmaceutical compositon comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-03-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | APOB, APOL1, SCARB1 | NPSR1 933/4885BRD4 848/4885ALOX15 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.